Aboleris Pharma Initiates Phase 1 Study Part II for ABO-21009
08 Jan 2026 //
PR NEWSWIRE
Aboleris Pharma Reveals New Preclinical Data On ABO21009
12 Nov 2025 //
PR NEWSWIRE
Aboleris Pharma Appoints Philippe Alen as Chief Business Officer
30 Oct 2025 //
PR NEWSWIRE
AbolerIS Doses 1st ABO21009 Patient in RA Ph1 Antibody Study
07 May 2025 //
PR NEWSWIRE
AbolerIS Pharma Announces Formation of Scientific Advisory Board
24 Apr 2025 //
PR NEWSWIRE

Market Place
Sourcing Support